Client on the Move - Noveome
Mission Viejo CA, February 8, 2021 Fallingst Technologies LLC, an advisory, asset management and valuation services firm headquartered in Mission Viejo CA, is lead advisor and facilitator of $60M Venture Capital Financing Structure for Noveome Biotherapeutics, Inc. (“Noveome”), a novel clinical-stage biopharmaceutical company.
Headquartered in Pittsburgh, PA – Noveome is a clinical-stage biopharmaceutical company specializing in the development of ST266, a novel, cell-free platform biologic that contains hundreds of growth factors and cytokines which act synergistically to modulate multiple biological pathways. The company continues to focus on improving clinical outcomes in a range of complex diseases and indications in categories as diverse as systemic inflammation, ophthalmology, neurology, dermatology and more.
About Fallingst Technologies
Fallingst Technologies LLC is a boutique advisory, asset management and valuation services firm, and the management services provider of the IPRESTIGE Fund. The firm helps clients use intellectual property assets and related technologies to leverage structured IP-backed non-dilutive debt financing transactions. Fallingst Technologies has extensive advisory and valuation services experience and knowledge with designing and implementing IP assessment and valuation programs that among other considerations are designed to provide maximum valuation and marketability of IP assets.
William J. Golden, CEO of Noveome added "we are delighted to be working with Joseph and his team to facilitate a non-dilutive venture capital structure that benefits our investors and employees. These funds will further our Secretome biotherapeutic clinical and product development program efforts." The company believes it holds significant promise to improve clinical outcomes in a range of complex diseases for a multitude health conditions across different therapeutic areas and routes of administration.
“We are thrilled to partner with Noveome on this endeavour and lead the facilitation of this important $60M venture capital financing structure to support the continued development of the world’s first cell-free platform biologic ST266,” said Joseph K. Hopkins, CEO of Fallingst Technologies. The firm's independent valuation services are designed to help Innovative companies such as Noveome gain and keep the upper hand on the competition, increase attention from the capital markets, and secure funding from investors by leveraging non-dilutive financing options that articulate the marketability strength and value of their intellectual property assets.